Table 2.
Analysis of lipid composition of the HDL changes from week 0 to week 12 in the placebo and policosanol groups.
| Placebo (n = 15) | Policosanol (n = 15) | ||||
|---|---|---|---|---|---|
| Week 0 | Week 12 | Week 0 | Week 12 | ||
| Cholesterol, mg/dL (in 2 mg/mL of protein) | 82.3 ± 0.8 | 79.0 ± 1.2† | 85.7 ± 3.6 | 82.5 ± 2.8 | |
| HDL2 | Triglyceride, mg/dL (in 2 mg/mL of protein) | 11.9 ± 0.3 | 13.8 ± 0.6* | 14.4 ± 0.5 | 12.9 ± 0.6 |
| FI, Glycated | 2,452 ± 91 | 2,453 ± 171 | 2,568 ± 225 | 2,152 ± 204* | |
| Cholesterol, mg/dL (in 2 mg/mL of protein) | 59.8 ± 1.9 | 41.3 ± 4.1* | 59.7 ± 2.7 | 61.3 ± 1.8 | |
| HDL3 | Triglyceride, mg/dL (in 2 mg/mL of protein) | 6.7 ± 0.6 | 6.2 ± 0.8 | 9.4 ± 0.5 | 7.1 ± 0.4* |
| FI, Glycated | 1817 ± 149 | 1911 ± 309 | 2,115 ± 197 | 1811 ± 154* | |
Values represent the mean ± standard error of the mean. *p < 0.05; †p < 0.01 vs. week 0 in each group. Placebo group, n = 15 and policosanol group, n = 15. HDL, high-density lipoprotein; FI, fluorescence intensity (Ex = 370 nm, Em = 440 nm, 0.01 mg/mL of protein).